114 related articles for article (PubMed ID: 20871640)
1. Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network.
Hohloch K; Zinzani PL; Linkesch W; Jurczak W; Deptala A; Lorsbach M; Windemuth-Kiesselbach C; Wulf GG; Truemper LH
Bone Marrow Transplant; 2011 Jun; 46(6):901-3. PubMed ID: 20871640
[No Abstract] [Full Text] [Related]
2. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
3. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
4. Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
Wondergem MJ; Zijlstra JM; de Rooij M; Visser OJ; Huijgens PC; Zweegman S
Br J Haematol; 2012 May; 157(3):395-7. PubMed ID: 22224561
[No Abstract] [Full Text] [Related]
5. [Radioimmunotherapy with (90)Y-Ibritumomab tiuxetan].
Brockmann H; Biersack HJ
Dtsch Med Wochenschr; 2006 Mar; 131(9):438-40. PubMed ID: 16493567
[No Abstract] [Full Text] [Related]
6. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
Ulaner GA; Colletti PM; Conti PS
Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
Zinzani PL; Gandolfi L; Stefoni V; Fanti S; Fina M; Pellegrini C; Montini GC; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):258-61. PubMed ID: 20709661
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Witzig TE
Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
[TBL] [Abstract][Full Text] [Related]
9. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
10. [Radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Spanish Nuclear Medicine Society].
Bello P; Almoguera MI; Pajares M; Olivas C; Lapeña L; Freire JM;
Rev Esp Med Nucl; 2010; 29(1):50-2. PubMed ID: 19963305
[No Abstract] [Full Text] [Related]
11. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
Tobinai K; Watanabe T; Ogura M; Morishima Y; Hotta T; Ishizawa K; Itoh K; Okamoto S; Taniwaki M; Tsukamoto N; Okumura H; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Endo K
Cancer Sci; 2009 Jan; 100(1):158-64. PubMed ID: 19018755
[TBL] [Abstract][Full Text] [Related]
12. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Storto G; De Renzo A; Pellegrino T; Perna F; De Falco T; Erra P; Nardelli A; Speranza A; Klain M; Rotoli B; Pace L
Radiology; 2010 Jan; 254(1):245-52. PubMed ID: 20032155
[TBL] [Abstract][Full Text] [Related]
13. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.
Gokhale AS; Mayadev J; Pohlman B; Macklis RM
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):194-201. PubMed ID: 16111589
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy for B-cell non-hodgkin lymphomas.
Tomblyn M
Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.
Vose JM; Bierman PJ; Loberiza FR; Bociek RG; Matso D; Armitage JO
Leuk Lymphoma; 2007 Apr; 48(4):683-90. PubMed ID: 17454625
[TBL] [Abstract][Full Text] [Related]
16. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
Meredith RF; Knox SJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
[TBL] [Abstract][Full Text] [Related]
17. [Contribution of radioimmunotherapy to the treatment of lymphoma].
Rizzo-Padoin N
Ann Pharm Fr; 2008; 66(5-6):300-8. PubMed ID: 19061730
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
Gisselbrecht C; Vose J; Nademanee A; Gianni AM; Nagler A
Oncologist; 2009; 14 Suppl 2():41-51. PubMed ID: 19819923
[TBL] [Abstract][Full Text] [Related]
19. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.
Shah J; Wang W; Harrough VD; Saville W; Meredith R; Shen S; Mueh J; Lister J; Jasthy S; Maggass G; McKay C; Krumdieck R; Tharp M; Winter C; Gregory S; Buchholz W; Awasthi S; Jacobs S; Chung H; Egner J; Lobuglio AF; Forero A
Leuk Lymphoma; 2007 Sep; 48(9):1736-44. PubMed ID: 17786709
[TBL] [Abstract][Full Text] [Related]
20. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Wiseman GA; Witzig TE
Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]